Successful treatment of refractory prurigo nodularis with abrocitinib
Key Clinical Message Prurigo nodularis is frequently difficult to manage with conventional therapy. Given the pathogenesis and refractory nature, we demonstrate a case in which inhibition of JAK–STAT signaling may significantly improve prurigo nodularis. Based on the results, we would like to draw a...
Main Authors: | Fang Sun, Zhenzhen Wu |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2024-03-01
|
Series: | Clinical Case Reports |
Subjects: | |
Online Access: | https://doi.org/10.1002/ccr3.8606 |
Similar Items
-
Dupilumab as promising treatment for prurigo nodularis: current evidences
by: Ludovica Toffoli, et al.
Published: (2022-04-01) -
Tofacitinib for Prurigo Nodularis: A Case Report
by: Peng C, et al.
Published: (2022-03-01) -
Prurigo nodularis in vitiligo patches: An unusual observation
by: Karim Saleh, MD, PhD
Published: (2020-09-01) -
Dupilumab for the treatment of prurigo nodularis: A systematic review
by: Peng Cao, et al.
Published: (2023-01-01) -
Spontaneous resolution of intractable prurigo nodularis after subinsular cortex stroke
by: Sakeen W. Kashem, MD, PhD, et al.
Published: (2023-02-01)